Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
PIVOT study is a multicenter, phase I/II clinical study designed to evaluate induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Phase I consists of a single-arm safety lead-in study evaluating the safety and preliminary efficacy of the investigational regimen. If predefined safety criteria are met, the study proceeds to a phase II randomized controlled trial comparing induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy with the standard PACIFIC regimen. The objective of the phase II study is to determine whether the investigational treatment strategy improves progression-free survival while maintaining an acceptable safety profile compared with the standard PACIFIC regimen.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat
- •Potwierdzony rozpoznaniem rak płuca bez przerzutów odległych (typ bez małych komórek)
- •Zaawansowany rak płuca (etap III) niemożliwy do operacyjnego usunięcia
- •Brak wcześniejszego leczenia raka
- •Wystarczająca funkcja narządów (wątroba, nerki, serce, płuca, krew)
- •Spodziewana długość życia co najmniej 3 miesiące
- •Zdolność do ukończenia leczenia i uczestnictwa w badaniu
✗ Disqualifies
- •Obecność małych komórek raka w badaniu histologicznym
- •Mutacja genu EGFR, przebudowa ALK lub ROS-1 w komórkach raka
- •Historia innego nowotworu w ciągu ostatnich 5 lat (z pewnymi wyjątkami)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Shanghai Chest Hospital
Shanghai, China
Trial contact
Wen Yu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.